2024 Q2 Form 10-Q Financial Statement
#000193341424000016 Filed on May 09, 2024
Income Statement
Concept | 2024 Q2 | 2024 Q1 | 2023 Q4 |
---|---|---|---|
Revenue | $0.00 | $0.00 | $0.00 |
YoY Change | |||
Cost Of Revenue | |||
YoY Change | |||
Gross Profit | |||
YoY Change | |||
Gross Profit Margin | |||
Selling, General & Admin | $5.895M | $4.608M | $4.026M |
YoY Change | 53.08% | 74.22% | 83.84% |
% of Gross Profit | |||
Research & Development | $39.27M | $30.75M | $23.69M |
YoY Change | 230.47% | 150.17% | 202.95% |
% of Gross Profit | |||
Depreciation & Amortization | $9.000K | $8.000K | |
YoY Change | |||
% of Gross Profit | |||
Operating Expenses | $45.17M | $35.36M | $27.71M |
YoY Change | 187.05% | 136.73% | 176.89% |
Operating Profit | -$45.17M | -$35.36M | |
YoY Change | 187.05% | 136.73% | |
Interest Expense | $4.152M | $3.853M | $3.321M |
YoY Change | 15.56% | 65.44% | 255.19% |
% of Operating Profit | |||
Other Income/Expense, Net | $4.154M | $3.854M | $1.000K |
YoY Change | 15.58% | 65.41% | |
Pretax Income | -$41.01M | -$31.51M | -$24.39M |
YoY Change | 237.81% | 149.9% | 168.81% |
Income Tax | |||
% Of Pretax Income | |||
Net Earnings | -$41.01M | -$31.50M | -$24.39M |
YoY Change | 237.81% | 150.0% | 168.81% |
Net Earnings / Revenue | |||
Basic Earnings Per Share | -$0.83 | -$0.70 | |
Diluted Earnings Per Share | -$0.83 | -$0.70 | -$0.61 |
COMMON SHARES | |||
Basic Shares Outstanding | 49.65M shares | 49.63M shares | 41.11M shares |
Diluted Shares Outstanding | 49.36M shares | 44.90M shares |
Balance Sheet
Concept | 2024 Q2 | 2024 Q1 | 2023 Q4 |
---|---|---|---|
SHORT-TERM ASSETS | |||
Cash & Short-Term Investments | $311.1M | $338.6M | $236.6M |
YoY Change | 19.16% | 25.1% | 114.85% |
Cash & Equivalents | $67.86M | $90.42M | $49.30M |
Short-Term Investments | $243.3M | $248.1M | $187.3M |
Other Short-Term Assets | $6.886M | $8.254M | $12.54M |
YoY Change | -17.94% | 78.08% | 364.12% |
Inventory | |||
Prepaid Expenses | |||
Receivables | |||
Other Receivables | |||
Total Short-Term Assets | $318.0M | $346.8M | $249.1M |
YoY Change | 18.0% | 25.99% | 120.81% |
LONG-TERM ASSETS | |||
Property, Plant & Equipment | $42.00K | $51.00K | $0.00 |
YoY Change | |||
Goodwill | |||
YoY Change | |||
Intangibles | |||
YoY Change | |||
Long-Term Investments | $0.00 | $0.00 | $2.482M |
YoY Change | -100.0% | -100.0% | |
Other Assets | $449.0K | $379.0K | $51.00K |
YoY Change | 780.39% | 871.79% | -96.87% |
Total Long-Term Assets | $491.0K | $430.0K | $2.533M |
YoY Change | -97.74% | -98.62% | 55.3% |
TOTAL ASSETS | |||
Total Short-Term Assets | $318.0M | $346.8M | $249.1M |
Total Long-Term Assets | $491.0K | $430.0K | $2.533M |
Total Assets | $318.5M | $347.2M | $251.6M |
YoY Change | 9.37% | 13.32% | 119.88% |
SHORT-TERM LIABILITIES | |||
YoY Change | |||
Accounts Payable | $1.707M | $4.261M | $601.0K |
YoY Change | -22.27% | 78.51% | -68.48% |
Accrued Expenses | $26.69M | $14.94M | $9.881M |
YoY Change | 565.42% | 82.83% | 79.3% |
Deferred Revenue | |||
YoY Change | |||
Short-Term Debt | $0.00 | $0.00 | $0.00 |
YoY Change | |||
Long-Term Debt Due | |||
YoY Change | |||
Total Short-Term Liabilities | $28.40M | $19.20M | $10.48M |
YoY Change | 357.5% | 81.86% | 29.94% |
LONG-TERM LIABILITIES | |||
Long-Term Debt | $0.00 | $0.00 | $0.00 |
YoY Change | |||
Other Long-Term Liabilities | |||
YoY Change | |||
Total Long-Term Liabilities | $0.00 | $0.00 | $0.00 |
YoY Change | |||
TOTAL LIABILITIES | |||
Total Short-Term Liabilities | $28.40M | $19.20M | $10.48M |
Total Long-Term Liabilities | $0.00 | $0.00 | $0.00 |
Total Liabilities | $28.40M | $19.20M | $10.48M |
YoY Change | 357.5% | 81.86% | 29.94% |
SHAREHOLDERS EQUITY | |||
Retained Earnings | -$197.2M | -$156.2M | -$124.7M |
YoY Change | 154.12% | 138.84% | 136.13% |
Common Stock | $5.000K | $5.000K | $4.000K |
YoY Change | 25.0% | 25.0% | 300.0% |
Preferred Stock | |||
YoY Change | |||
Treasury Stock (at cost) | |||
YoY Change | |||
Treasury Stock Shares | |||
Shareholders Equity | $290.1M | $328.0M | $241.2M |
YoY Change | |||
Total Liabilities & Shareholders Equity | $318.5M | $347.2M | $251.6M |
YoY Change | 9.37% | 13.32% | 119.88% |
Cashflow Statement
Concept | 2024 Q2 | 2024 Q1 | 2023 Q4 |
---|---|---|---|
OPERATING ACTIVITIES | |||
Net Income | -$41.01M | -$31.50M | -$24.39M |
YoY Change | 237.81% | 150.0% | 168.81% |
Depreciation, Depletion And Amortization | $9.000K | $8.000K | |
YoY Change | |||
Cash From Operating Activities | -$30.15M | -$19.10M | -$28.98M |
YoY Change | 47.88% | 49.22% | 184.52% |
INVESTING ACTIVITIES | |||
Capital Expenditures | $0.00 | $59.00K | |
YoY Change | |||
Acquisitions | |||
YoY Change | |||
Other Investing Activities | $7.736M | -$55.89M | -$8.089M |
YoY Change | -147.93% | -60.15% | -116.18% |
Cash From Investing Activities | $7.736M | -$55.95M | -$8.089M |
YoY Change | -147.93% | -60.11% | -116.18% |
FINANCING ACTIVITIES | |||
Cash Dividend Paid | |||
YoY Change | |||
Common Stock Issuance & Retirement, Net | |||
YoY Change | |||
Debt Paid & Issued, Net | |||
YoY Change | |||
Cash From Financing Activities | -152.0K | $116.2M | 74.00K |
YoY Change | -73.84% | -42.92% | -106.93% |
NET CHANGE | |||
Cash From Operating Activities | -30.15M | -$19.10M | -28.98M |
Cash From Investing Activities | 7.736M | -$55.95M | -8.089M |
Cash From Financing Activities | -152.0K | $116.2M | 74.00K |
Net Change In Cash | -22.56M | $41.11M | -37.00M |
YoY Change | -39.2% | -18.66% | -195.48% |
FREE CASH FLOW | |||
Cash From Operating Activities | -$30.15M | -$19.10M | -$28.98M |
Capital Expenditures | $0.00 | $59.00K | |
Free Cash Flow | -$30.15M | -$19.16M | |
YoY Change |
Facts In Submission
Frame | Concept Type | Concept / XBRL Key | Value | Unit |
---|---|---|---|---|
CY2023Q1 | us-gaap |
Stockholders Equity Note Stock Split Conversion Ratio1
StockholdersEquityNoteStockSplitConversionRatio1
|
0.0926 | |
CY2024Q1 | us-gaap |
General And Administrative Expense
GeneralAndAdministrativeExpense
|
4608000 | usd |
CY2023Q1 | us-gaap |
General And Administrative Expense
GeneralAndAdministrativeExpense
|
2645000 | usd |
CY2024Q1 | us-gaap |
Operating Expenses
OperatingExpenses
|
35362000 | usd |
CY2023Q1 | us-gaap |
Operating Expenses
OperatingExpenses
|
14938000 | usd |
CY2024Q1 | us-gaap |
Operating Income Loss
OperatingIncomeLoss
|
-35362000 | usd |
CY2023Q1 | us-gaap |
Operating Income Loss
OperatingIncomeLoss
|
-14938000 | usd |
CY2024Q1 | us-gaap |
Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
|
3853000 | usd |
CY2023Q1 | us-gaap |
Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
|
2329000 | usd |
CY2024Q1 | us-gaap |
Other Nonoperating Income
OtherNonoperatingIncome
|
1000 | usd |
CY2023Q1 | us-gaap |
Other Nonoperating Income
OtherNonoperatingIncome
|
1000 | usd |
CY2024Q1 | us-gaap |
Nonoperating Income Expense
NonoperatingIncomeExpense
|
3854000 | usd |
CY2023Q1 | us-gaap |
Nonoperating Income Expense
NonoperatingIncomeExpense
|
2330000 | usd |
CY2024Q1 | us-gaap |
Net Income Loss
NetIncomeLoss
|
-31508000 | usd |
CY2023Q1 | us-gaap |
Net Income Loss
NetIncomeLoss
|
-12608000 | usd |
CY2024Q1 | us-gaap |
Earnings Per Share Basic
EarningsPerShareBasic
|
-0.70 | |
CY2024Q1 | us-gaap |
Earnings Per Share Diluted
EarningsPerShareDiluted
|
-0.70 | |
CY2023Q1 | us-gaap |
Earnings Per Share Diluted
EarningsPerShareDiluted
|
-0.51 | |
CY2023Q1 | us-gaap |
Earnings Per Share Basic
EarningsPerShareBasic
|
-0.51 | |
CY2024Q1 | us-gaap |
Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
|
44900755 | shares |
CY2024Q1 | us-gaap |
Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
|
44900755 | shares |
CY2023Q1 | us-gaap |
Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
|
24764469 | shares |
CY2023Q1 | us-gaap |
Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
|
24764469 | shares |
CY2022Q4 | us-gaap |
Stockholders Equity
StockholdersEquity
|
-52269000 | usd |
CY2023Q1 | us-gaap |
Stock Issued During Period Value Conversion Of Convertible Securities
StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
|
158644000 | usd |
CY2023Q1 | us-gaap |
Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
|
201359000 | usd |
CY2023Q1 | us-gaap |
Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
|
749000 | usd |
CY2023Q1 | us-gaap |
Net Income Loss
NetIncomeLoss
|
-12608000 | usd |
CY2023Q1 | us-gaap |
Stockholders Equity
StockholdersEquity
|
295875000 | usd |
CY2023Q4 | us-gaap |
Stockholders Equity
StockholdersEquity
|
241154000 | usd |
CY2024Q1 | us-gaap |
Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
|
116059000 | usd |
CY2024Q1 | us-gaap |
Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
|
149000 | usd |
CY2024Q1 | us-gaap |
Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
|
2191000 | usd |
CY2024Q1 | us-gaap |
Net Income Loss
NetIncomeLoss
|
-31508000 | usd |
CY2024Q1 | us-gaap |
Stockholders Equity
StockholdersEquity
|
328045000 | usd |
CY2024Q1 | us-gaap |
Net Income Loss
NetIncomeLoss
|
-31508000 | usd |
CY2023Q1 | us-gaap |
Net Income Loss
NetIncomeLoss
|
-12608000 | usd |
CY2024Q1 | us-gaap |
Accretion Amortization Of Discounts And Premiums Investments
AccretionAmortizationOfDiscountsAndPremiumsInvestments
|
2509000 | usd |
CY2023Q1 | us-gaap |
Accretion Amortization Of Discounts And Premiums Investments
AccretionAmortizationOfDiscountsAndPremiumsInvestments
|
855000 | usd |
CY2024Q1 | us-gaap |
Share Based Compensation
ShareBasedCompensation
|
2191000 | usd |
CY2023Q1 | us-gaap |
Share Based Compensation
ShareBasedCompensation
|
749000 | usd |
CY2024Q1 | us-gaap |
Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
|
8000 | usd |
CY2023Q1 | us-gaap |
Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
|
0 | usd |
CY2024Q1 | us-gaap |
Increase Decrease In Accrued Interest Receivable Net
IncreaseDecreaseInAccruedInterestReceivableNet
|
-119000 | usd |
CY2023Q1 | us-gaap |
Increase Decrease In Accrued Interest Receivable Net
IncreaseDecreaseInAccruedInterestReceivableNet
|
270000 | usd |
CY2024Q1 | us-gaap |
Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
|
-4159000 | usd |
CY2023Q1 | us-gaap |
Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
|
1703000 | usd |
CY2024Q1 | us-gaap |
Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
|
8401000 | usd |
CY2023Q1 | us-gaap |
Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
|
1912000 | usd |
CY2024Q1 | us-gaap |
Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
|
-19139000 | usd |
CY2023Q1 | us-gaap |
Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
|
-12775000 | usd |
CY2024Q1 | us-gaap |
Payments To Acquire Held To Maturity Securities
PaymentsToAcquireHeldToMaturitySecurities
|
123393000 | usd |
CY2023Q1 | us-gaap |
Payments To Acquire Held To Maturity Securities
PaymentsToAcquireHeldToMaturitySecurities
|
162751000 | usd |
CY2024Q1 | us-gaap |
Proceeds From Maturities Prepayments And Calls Of Held To Maturity Securities
ProceedsFromMaturitiesPrepaymentsAndCallsOfHeldToMaturitySecurities
|
67500000 | usd |
CY2023Q1 | us-gaap |
Proceeds From Maturities Prepayments And Calls Of Held To Maturity Securities
ProceedsFromMaturitiesPrepaymentsAndCallsOfHeldToMaturitySecurities
|
22500000 | usd |
CY2024Q1 | us-gaap |
Payments To Acquire Productive Assets
PaymentsToAcquireProductiveAssets
|
59000 | usd |
CY2023Q1 | us-gaap |
Payments To Acquire Productive Assets
PaymentsToAcquireProductiveAssets
|
0 | usd |
CY2024Q1 | us-gaap |
Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
|
-55952000 | usd |
CY2023Q1 | us-gaap |
Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
|
-140251000 | usd |
CY2024Q1 | us-gaap |
Proceeds From Issuance Of Private Placement
ProceedsFromIssuanceOfPrivatePlacement
|
116119000 | usd |
CY2023Q1 | us-gaap |
Proceeds From Issuance Of Private Placement
ProceedsFromIssuanceOfPrivatePlacement
|
0 | usd |
CY2024Q1 | us-gaap |
Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
|
149000 | usd |
CY2023Q1 | us-gaap |
Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
|
0 | usd |
CY2024Q1 | us-gaap |
Payments Of Stock Issuance Costs
PaymentsOfStockIssuanceCosts
|
63000 | usd |
CY2023Q1 | us-gaap |
Payments Of Stock Issuance Costs
PaymentsOfStockIssuanceCosts
|
0 | usd |
CY2024Q1 | us-gaap |
Proceeds From Issuance Initial Public Offering
ProceedsFromIssuanceInitialPublicOffering
|
0 | usd |
CY2023Q1 | us-gaap |
Proceeds From Issuance Initial Public Offering
ProceedsFromIssuanceInitialPublicOffering
|
203571000 | usd |
CY2024Q1 | us-gaap |
Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
|
116205000 | usd |
CY2023Q1 | us-gaap |
Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
|
203571000 | usd |
CY2024Q1 | us-gaap |
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
|
41114000 | usd |
CY2023Q1 | us-gaap |
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
|
50545000 | usd |
CY2023Q4 | us-gaap |
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
|
49304000 | usd |
CY2022Q4 | us-gaap |
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
|
87701000 | usd |
CY2024Q1 | us-gaap |
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
|
90418000 | usd |
CY2023Q1 | us-gaap |
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
|
138246000 | usd |
CY2024Q1 | mlys |
Offering Costs Incurred During Noncash Or Partial Noncash Transaction
OfferingCostsIncurredDuringNoncashOrPartialNoncashTransaction
|
321000 | usd |
CY2023Q1 | mlys |
Offering Costs Incurred During Noncash Or Partial Noncash Transaction
OfferingCostsIncurredDuringNoncashOrPartialNoncashTransaction
|
581000 | usd |
CY2024Q1 | us-gaap |
Conversion Of Stock Amount Converted1
ConversionOfStockAmountConverted1
|
0 | usd |
CY2023Q1 | us-gaap |
Conversion Of Stock Amount Converted1
ConversionOfStockAmountConverted1
|
159180000 | usd |
CY2024Q1 | us-gaap |
Debt Securities Held To Maturity Amortized Cost After Allowance For Credit Loss
DebtSecuritiesHeldToMaturityAmortizedCostAfterAllowanceForCreditLoss
|
248100000 | usd |
CY2024Q1 | us-gaap |
Investments And Cash
InvestmentsAndCash
|
338600000 | usd |
CY2023Q1 | us-gaap |
Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
|
0.0001 | |
CY2024Q1 | us-gaap |
Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
|
-156200000 | usd |
CY2024Q1 | us-gaap |
Investments And Cash
InvestmentsAndCash
|
338600000 | usd |
CY2024Q1 | us-gaap |
Net Income Loss
NetIncomeLoss
|
-31500000 | usd |
CY2024Q1 | us-gaap |
Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
|
-19100000 | usd |
us-gaap |
Proceeds From Issuance Or Sale Of Equity
ProceedsFromIssuanceOrSaleOfEquity
|
498800000 | usd | |
CY2024Q1 | us-gaap |
Number Of Operating Segments
NumberOfOperatingSegments
|
1 | segment |
CY2024Q1 | us-gaap |
Use Of Estimates
UseOfEstimates
|
<div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Use of Estimates </span></div>The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of income and expenses during the reporting period. Actual results could differ from those estimates. Estimates have been used in the following areas, among others: research and development accruals, fair value of the Company’s common stock prior to the closing of the Company’s IPO, and income taxes. | |
CY2024Q1 | us-gaap |
Restricted Cash
RestrictedCash
|
0 | usd |
CY2023Q4 | us-gaap |
Restricted Cash
RestrictedCash
|
0 | usd |
CY2024Q1 | us-gaap |
Cash
Cash
|
5376000 | usd |
CY2023Q4 | us-gaap |
Cash
Cash
|
643000 | usd |
CY2024Q1 | us-gaap |
Cash Equivalents At Carrying Value
CashEquivalentsAtCarryingValue
|
85042000 | usd |
CY2023Q4 | us-gaap |
Cash Equivalents At Carrying Value
CashEquivalentsAtCarryingValue
|
48661000 | usd |
CY2024Q1 | us-gaap |
Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
|
90418000 | usd |
CY2023Q4 | us-gaap |
Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
|
49304000 | usd |
CY2024Q1 | us-gaap |
Concentration Risk Credit Risk
ConcentrationRiskCreditRisk
|
<div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Concentration of Credit Risk </span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has no significant off-balance sheet concentrations of credit risk, such as foreign currency exchange contracts, option contracts, or other hedging arrangements. Financial instruments that </span></div>potentially subject the Company to concentrations of credit risk primarily consist of cash balances in several accounts with three financial institutions which, from time to time, are in excess of federally insured limits. | |
CY2024Q1 | us-gaap |
Deferred Offering Costs
DeferredOfferingCosts
|
300000 | usd |
CY2023Q4 | us-gaap |
Deferred Offering Costs
DeferredOfferingCosts
|
0 | usd |
CY2023Q1 | us-gaap |
Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
|
749000 | usd |
CY2024Q1 | ecd |
Non Rule10b51 Arr Adopted Flag
NonRule10b51ArrAdoptedFlag
|
false | |
CY2024Q1 | ecd |
Rule10b51 Arr Adopted Flag
Rule10b51ArrAdoptedFlag
|
true | |
CY2024Q1 | ecd |
Rule10b51 Arr Trmntd Flag
Rule10b51ArrTrmntdFlag
|
false | |
CY2024Q1 | ecd |
Non Rule10b51 Arr Trmntd Flag
NonRule10b51ArrTrmntdFlag
|
false | |
CY2024Q1 | us-gaap |
Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
|
5219286 | shares |
CY2023Q1 | us-gaap |
Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
|
3670597 | shares |
CY2024Q1 | us-gaap |
Debt Securities Held To Maturity Amortized Cost After Allowance For Credit Loss
DebtSecuritiesHeldToMaturityAmortizedCostAfterAllowanceForCreditLoss
|
248147000 | usd |
CY2024Q1 | us-gaap |
Held To Maturity Securities Fair Value
HeldToMaturitySecuritiesFairValue
|
248050000 | usd |
CY2023Q4 | us-gaap |
Debt Securities Held To Maturity Amortized Cost After Allowance For Credit Loss Current
DebtSecuritiesHeldToMaturityAmortizedCostAfterAllowanceForCreditLossCurrent
|
187263000 | usd |
CY2023Q4 | us-gaap |
Debt Securities Held To Maturity Fair Value Current
DebtSecuritiesHeldToMaturityFairValueCurrent
|
187293000 | usd |
CY2023Q4 | us-gaap |
Debt Securities Held To Maturity Amortized Cost After Allowance For Credit Loss Noncurrent
DebtSecuritiesHeldToMaturityAmortizedCostAfterAllowanceForCreditLossNoncurrent
|
2482000 | usd |
CY2023Q4 | us-gaap |
Debt Securities Held To Maturity Fair Value Noncurrent
DebtSecuritiesHeldToMaturityFairValueNoncurrent
|
2486000 | usd |
CY2023Q4 | us-gaap |
Debt Securities Held To Maturity Amortized Cost After Allowance For Credit Loss
DebtSecuritiesHeldToMaturityAmortizedCostAfterAllowanceForCreditLoss
|
189745000 | usd |
CY2023Q4 | us-gaap |
Held To Maturity Securities Fair Value
HeldToMaturitySecuritiesFairValue
|
189779000 | usd |
CY2024Q1 | mlys |
Accrued Research And Development Costs Current
AccruedResearchAndDevelopmentCostsCurrent
|
12857000 | usd |
CY2023Q4 | mlys |
Accrued Research And Development Costs Current
AccruedResearchAndDevelopmentCostsCurrent
|
7122000 | usd |
CY2024Q1 | us-gaap |
Accrued Employee Benefits Current
AccruedEmployeeBenefitsCurrent
|
662000 | usd |
CY2023Q4 | us-gaap |
Accrued Employee Benefits Current
AccruedEmployeeBenefitsCurrent
|
1599000 | usd |
CY2024Q1 | us-gaap |
Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
|
1424000 | usd |
CY2023Q4 | us-gaap |
Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
|
1160000 | usd |
CY2024Q1 | us-gaap |
Accrued Liabilities Current
AccruedLiabilitiesCurrent
|
14943000 | usd |
CY2023Q4 | us-gaap |
Accrued Liabilities Current
AccruedLiabilitiesCurrent
|
9881000 | usd |
CY2024Q1 | us-gaap |
Common Stock Capital Shares Reserved For Future Issuance
CommonStockCapitalSharesReservedForFutureIssuance
|
8584725 | shares |
CY2023Q1 | us-gaap |
Common Stock Shares Authorized
CommonStockSharesAuthorized
|
500000000 | shares |
CY2023Q1 | us-gaap |
Temporary Equity Shares Authorized
TemporaryEquitySharesAuthorized
|
50000000 | shares |
CY2024Q1 | mlys |
Sale Of Warrants Number Of Shares Issued In Transaction
SaleOfWarrantsNumberOfSharesIssuedInTransaction
|
549755 | shares |
CY2024Q1 | mlys |
Sale Of Warrants Price Per Share
SaleOfWarrantsPricePerShare
|
13.499 | |
CY2024Q1 | us-gaap |
Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1
ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
|
0.001 | |
CY2024Q1 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
|
4251075 | shares |
CY2024Q1 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Available For Grant
ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
|
2981285 | shares |
CY2024Q1 | us-gaap |
Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
|
2191000 | usd |